Discover 5-Amino-1MQ, a small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT). Also known as 5-amino-1-methylquinolinium, this compound is studied for its ability to modulate cellular NAD+ metabolism and adipocyte function. Although frequently grouped with research peptides, 5-Amino-1MQ is a low-molecular-weight organic molecule rather than a peptide.
NNMT is highly expressed in adipose tissue and catalyzes the methylation of nicotinamide (a NAD+ precursor) to 1-methylnicotinamide (1-MNA), consuming S-adenosylmethionine (SAM) in the process. By inhibiting NNMT, 5-Amino-1MQ reduces 1-MNA production and supports higher intracellular levels of NAD+ and SAM, particularly in fat cells.
Key Research Areas of Interest for 5-Amino-1MQ
• Preclinical evidence of reduced body weight and white adipose tissue mass in diet-induced obese mouse models without changes in food intake.
• Suppression of lipogenesis and reduced adipocyte size observed in cell and animal studies.
• Elevation of intracellular NAD+ and SAM levels in adipocytes, with potential downstream effects on energy metabolism and sirtuin activity.
• Investigation of insulin sensitivity, plasma cholesterol, and overall metabolic parameters in rodent obesity models.
• Research interest in body composition, muscle preservation during fat loss phases, and NAD+-related cellular pathways.
• Exploration as a tool compound for studying NNMT biology in metabolic disease research.
• Often used in combination with MOTS-c, Retatrutide and SLU-PP-332
How 5-Amino-1MQ Works
5-Amino-1MQ selectively inhibits NNMT (reported IC50 approximately 1.2 µM in key studies). This blockade:
• Limits conversion of nicotinamide to 1-MNA.
• Increases availability of nicotinamide for the NAD+ salvage pathway.
• Raises intracellular NAD+ and SAM concentrations in adipocytes.
• Suppresses lipogenesis and promotes a metabolic shift that favors reduced fat storage in preclinical models.
Landmark work (including Neelakantan et al., 2018) demonstrated these effects in diet-induced obese mice, with reductions in body weight, adipose mass, adipocyte size, and plasma total cholesterol after short-term systemic administration, without observable adverse effects or changes in food intake in the reported studies.
Dosing & Administration Considerations in Research
Published animal studies commonly used intraperitoneal or subcutaneous dosing around 20 mg/kg (multiple times daily). In research and community contexts, oral administration of 50–150 mg per day is frequently discussed, often in short cycles. No established human therapeutic dose exists. 5-Amino-1MQ is typically supplied as powder or capsules for research use and is not formulated as an injectable peptide.
5-Amino-1MQ is not FDA-approved for any indication and remains a research chemical. Human clinical trial data are limited or absent in the published literature.
Common Side Effects & Safety Profile
Preclinical studies reported no major observable adverse effects at the doses tested. Human safety data are sparse; anecdotal reports occasionally mention mild gastrointestinal discomfort, headache, or transient effects. Long-term safety, drug interactions, and effects in specific populations have not been systematically established. Use only under appropriate research or medical oversight.
Critical Disclaimer: 5-Amino-1MQ is intended strictly for laboratory research or use under qualified supervision. It is not an FDA-approved drug or dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease. Not for self-administration or human consumption outside authorized research settings. Source only from reputable suppliers providing third-party purity testing and Certificates of Analysis. Consult a licensed healthcare professional before any consideration of use. Results from animal studies do not guarantee human outcomes.
Support advanced metabolic and NNMT-pathway research with high-purity 5-Amino-1MQ. Verify testing documentation and prioritize quality-sourced material for reproducible results.
Rebecca –
Very happy with this and the mots-c thank you!
Jesse –
5/5!